Drugdocs | Yondelis®

Drug updated on 3/28/2024

Dosage Form	Injection (intravenous; 1 mg)
Drug Class	Alkylating agents
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Trabectedin (Yondelis) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Two systematic reviews/meta-analyses were reviewed to gather information about this drug.
A study examining the efficacy/effectiveness of trabectedin in previously treated metastatic synovial sarcoma reported poor outcomes across agents and settings, highlighting a need for novel treatments with improved efficacy.
The pooled median overall survival was 10.4 months and overall response rate was 14.7% in studies involving trabectedin; these results were consistent across real-world and clinical trial settings.
Another review focusing on cardiac safety found an estimated incidence of cardiac toxicity at 3,4% among patients receiving trabectedin, suggesting a higher rate of heart failure than previously recognized especially among those exposed to previous or concomitant anthracyclines therapy.
This same review suggested that assaying for NT-pro-BNP may be useful for early detection of individuals experiencing heart failure induced by Trabectedin (Yondelis).

Document Title	Year	Source
Yondelis (trabectedin) Prescribing Information.	2020	Janssen Products, LP, Horsham, PA

Document Title	Year	Source
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).	2022	Future Oncology
Trabectedin-Related Heart Failure: Case Report and a Systematic Review of the Literature	2021	Frontiers in oncology